Arcturus Therapeutics Holdings Inc. Stock News

Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated v

The following slide deck was published by Arcturus Therapeutics Holdings Inc. in conjunction with this event..

SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on

I demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.

SG Americas Securities LLC purchased a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securitie

Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus T

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -3.77% and -54.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810

Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nationally recognized leader in corporate life sciences transactionsSAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT),

Individual investors are placing their bets on biotech companies pursuing coronavirus advances. Some invest for fun and profit, while others want to be a part of a historic breakthrough.

Novovax shares have climbed nearly 4,000% so far this year on excitement over the company’s Covid-19 vaccine.

MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials. Vaccines developed using different vectors have different advantages and disadvantages.

Investors can count on these growth stocks to deliver consistent, positive returns for the remainder of this year and beyond.

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on